<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512729</url>
  </required_header>
  <id_info>
    <org_study_id>DoCPI</org_study_id>
    <nct_id>NCT04512729</nct_id>
  </id_info>
  <brief_title>Detection Of Colonic Polyps In India: Diagnostic Colonoscopy</brief_title>
  <acronym>DoCPI</acronym>
  <official_title>Detection Of Colonic Polyps In India: Diagnostic Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian Institute of Gastroenterology, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asian Institute of Gastroenterology, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal carcinoma (CRC) is the third most common cancer in male and female worldwide. In&#xD;
      India, it is the fourth most common cause of cancer in males and third most common cancer in&#xD;
      female. Age, smoking, colonic adenomatous polyp, family history are traditional risk factor&#xD;
      for CRC. The vast majority of CRC results from malignant transformation from adenoma, which&#xD;
      is called as adenoma carcinoma sequence. These adenomatous polyps grows slowly over many&#xD;
      years and malignant transformation eventually occurs over 10 years. So, the early detection&#xD;
      and removal of polyp at early stage should benefit in preventing CRC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The third most common cancer in both male and female is colorectal carcinoma (CRC) worldwide.&#xD;
      In India, it is the fourth most common cause of cancer in males and third most common cancer&#xD;
      in females. The age - standardized rates of CRC in India have been estimated to be 4.2 and&#xD;
      3.2/100000 for males and females, respectively. Age, smoking and colonic adenoma along with&#xD;
      family history is considered as traditional risk factors for CRC. The US National Polyp study&#xD;
      demonstrated that colonoscopy and polypectomy could prevent 76% to 90% of colorectal cancers.&#xD;
      The vast majority of CRC result from malignant transformation from adenomas. This is called&#xD;
      adenoma - carcinoma sequence, these adenomatous polyps grows slowly over many years and&#xD;
      malignant transformation eventually occurs. The time span for this transformation is on an&#xD;
      average 10 years. So, the detection and removal of polyp at early stage on adenoma -&#xD;
      carcinoma sequence should benefit in preventing CRC.&#xD;
&#xD;
      The prevalence of adenoma, utilization of colonoscopy for its detection and subsequent&#xD;
      reduction in CRC has been well studied and established in western population. This has led to&#xD;
      formulation of national screening colonoscopy programs elsewhere. However, data from Indian&#xD;
      subcontinent is scanty. In current study, at a large tertiary care center, we aimed to study&#xD;
      prevalence of colonic polyps and adenoma who are undergoing diagnostic colonoscopy using high&#xD;
      definition colonoscopy and characterizing with Narrow Band Imaging and to find associated&#xD;
      demographic, social, personal and family related risk factors in patients with adenomas.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      This will be a prospective, single center, observational study. All subjects referred for&#xD;
      diagnostic colonoscopy will be prospectively enrolled.&#xD;
&#xD;
      Enrollment:&#xD;
&#xD;
      All subjects referred for the diagnostic colonoscopy will be enrolled. A member of the&#xD;
      research team will approach each subject to discuss participation in the study, including&#xD;
      background of the proposed study, inclusion and exclusion criteria, benefits and risks of the&#xD;
      procedures and follow-up. If this is of interest to the subject, the informed consent form is&#xD;
      discussed and presented. The subject must sign the consent form prior to enrollment. This&#xD;
      form will have prior approval of the study site's Institutional Review Board (IRB). Failure&#xD;
      to obtain informed consent renders the subject ineligible for the study.&#xD;
&#xD;
      Study equipment&#xD;
&#xD;
      Colonoscope:&#xD;
&#xD;
      Olympus HDWL colonoscope will be used to perform colonoscopies. Technical specifications&#xD;
      include outer diameter 13.2 mm, instrument channel diameter 3.7 mm, air-water suction&#xD;
      channels, field of view 170 degrees, 4-way angulations (180 degrees up and 180 degrees down,&#xD;
      160 degrees right and left), working length, 168 cm.&#xD;
&#xD;
      Colonoscopy procedure and definitions&#xD;
&#xD;
      For all patients, either moderate sedation with intravenous midazolam or conscious sedation&#xD;
      with intravenous propofol will be administered in a standard fashion prior to undergoing&#xD;
      colonoscopy.&#xD;
&#xD;
      The colonoscope will be inserted and cecum will be intubated. Photo documentation of the&#xD;
      cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of&#xD;
      the colonoscope.&#xD;
&#xD;
      The time from the point of insertion of the colonoscope into the rectum to the intubation of&#xD;
      cecum will be recorded with a stop watch by a research coordinator and will be documented as&#xD;
      the &quot;insertion time&quot;.&#xD;
&#xD;
      The time spent in inspecting the mucosa during withdrawal of the colonoscope will be&#xD;
      documented as the &quot;withdrawal time&quot;. During withdrawal of the colonoscope the stop watch will&#xD;
      be stopped whenever mucosa is being cleaned, fluid/solid debris is suctioned or a polyp is&#xD;
      being removed to ensure that the withdrawal time is the actual representation of the mucosal&#xD;
      inspection time. Meticulous technique will be employed during the withdrawal phase with&#xD;
      special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral&#xD;
      folds, flexures and valves.&#xD;
&#xD;
      All polyps detected will be documented: size, location, and morphology (using the Paris&#xD;
      classification - Appendix A and Narrow Band Imaging classification - NICE and JNET). Photo&#xD;
      documentation of the polyps will be performed.&#xD;
&#xD;
      Polyps will then be removed with a biopsy forceps or snare and sent for histopathological&#xD;
      evaluation, each in a separate jar and labeled accordingly.&#xD;
&#xD;
      The bowel preparation will be evaluated and graded according to previously reported criteria&#xD;
      using the Boston Bowel Preparation Scale. Complications including post colonoscopy pain,&#xD;
      perforation or gastrointestinal bleeding (requiring intervention) will be recorded.&#xD;
&#xD;
      Adverse events:&#xD;
&#xD;
      The primary investigator at each site will monitor any adverse events reported to the study&#xD;
      staff and determine if it's related to the study procedures including standard colonoscopy at&#xD;
      the respective site. All adverse events will be monitored until a satisfactory resolution and&#xD;
      will be reported to the local IRB within 5 days of knowledge. A table will be maintained for&#xD;
      the adverse events in each arm and in case of any statistically significant adverse even rate&#xD;
      in any arm, the primary investigator will make the decision to remove the treatment arm or&#xD;
      stop the study. Because the risks of this proposed study are low, this program will not&#xD;
      require a Data Safety and Monitoring Board. Instead, the Principal Investigator and clinical&#xD;
      Site Investigators performing the endoscopies will be responsible for implementing a detailed&#xD;
      Data and Safety Monitoring plan in compliance with the IRB guidelines.&#xD;
&#xD;
      Data integrity and safety:&#xD;
&#xD;
      All paper charts pertaining to the patient will be kept under lock and key in coordinators&#xD;
      office away from the endoscopy area. The data will be entered in to a data base weekly after&#xD;
      collection of histology reports. The data is password protected and stored on the AIG&#xD;
      internal server where it will remain throughout the study. Computers and/or files will be&#xD;
      password-protected. Only approved personnel by the IRB will have access to the file storage.&#xD;
&#xD;
      To protect subject confidentiality, each subject will be assigned a case study number. The&#xD;
      subject's name is not to appear anywhere on the Case Report Forms (CRF's) or supporting&#xD;
      documentation. A study log with the identifiable information will be kept in a separate&#xD;
      folder to enable the investigators to assist in any research audit. No procedural data except&#xD;
      the date of examination will be entered in to this log.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Colonic Adenoma</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate prevalence of colonic polyps and adenomas in Indian Population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for Colonic adenoma</measure>
    <time_frame>1 year</time_frame>
    <description>1. To find possible risk factors associated with colonic adenoma to plan CRC screening program</description>
  </secondary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Colonic Polyp</condition>
  <condition>Colonic Adenoma</condition>
  <condition>Colonic Neoplasms</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.&#xD;
The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.&#xD;
The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the &quot;withdrawal time&quot;. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects referred for the diagnostic colonoscopy will be enrolled. A member of the&#xD;
        research team will approach each subject to discuss participation in the study, including&#xD;
        background of the proposed study, inclusion and exclusion criteria, benefits and risks of&#xD;
        the procedures and follow-up. If this is of interest to the subject, the informed consent&#xD;
        form is discussed and presented. The subject must sign the consent form prior to&#xD;
        enrollment. This form will have prior approval of the study site's Institutional Review&#xD;
        Board (IRB). Failure to obtain informed consent renders the subject ineligible for the&#xD;
        study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Referral for diagnostic colonoscopy&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Inability or not willing to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>D Nageshwar Reddy, MD,DM</last_name>
    <phone>914023378888</phone>
    <email>aigindia@yahoo.co.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nitin Jagtap, MD, DNB</last_name>
    <phone>914023378888</phone>
    <email>docnits13@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>D Nageshwar Reddy</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Nageshwar Reddy, MD, DM</last_name>
      <phone>914023378888</phone>
      <email>aigindia@yahoo.co.in</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian Institute of Gastroenterology, India</investigator_affiliation>
    <investigator_full_name>Mohan Ramchandani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Colonic Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No data will be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

